For the full list of speakers and event information, visit our event site.
In many ways, 2017 marked a turning point for biomedical innovation. The FDA approved the first U.S. gene therapy, the first CAR-T cellular immunotherapy, the first cancer drug based on a genetic signature, and the first smartphone app to treat substance abuse. Add to that the first successful Phase 3 trial for an RNA interference drug, and 2017 was a year in which medicine began to change significantly.
Yet with those changes come significant questions. How will the U.S. healthcare system handle these newer, longer-lasting treatments? Will there finally be a drug price reckoning as new therapies push costs higher—and will biopharma adapt with innovative payment models? Elsewhere, will setbacks emerge as CRISPR-Cas9 gene editing speeds towards human testing? Will combination treatments expand the reach of cancer immunotherapy, or pose new obstacles? The list of questions is also formidable and comes amidst changes at the FDA and rising political activism among biopharma leaders.
Visit our website to see the full list of speakers.
Registration & Networking: 12:30 pm – 1:30 pm
Program: 1:30 pm – 5:30 pm
Networking reception: 5:30 pm – 6:30 pm
Tickets are transferable but not refundable.
To inquire about press registration, contact firstname.lastname@example.org.
*Speakers and program schedule are subject to change.
Speakers: @FishRichardson @ICONplc @sanofi @eric_lander @zhangf @karaemiller @CKadoch
Short URL: http://bit.ly/xconbio18